<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03559439</url>
  </required_header>
  <id_info>
    <org_study_id>PTA001</org_study_id>
    <nct_id>NCT03559439</nct_id>
  </id_info>
  <brief_title>CD19-targeting CAR T Cells in Relapsed or Refractory CD19 Positive B-cell Malignancies</brief_title>
  <official_title>CD19-targeting CAR T Cell Therapy in the Treatment of Relapsed or Refractory CD19 Positive B-cell Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Tong Ren Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gracell Biotechnology Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Tong Ren Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single center, single arm, open-label phase 1 study to determine the safety and&#xD;
      efficacy of autologous T cells expressing CD19 chimeric antigen receptors in adults with&#xD;
      CD19+ B cell malignancies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-center, Open Label phase I clinical trial, 9 subjects planned to be&#xD;
      enrolled. The subjects will be divided into low-dose group, medium-dose group and high-dose&#xD;
      group.Dose CAR+ cells/kg Low 1×105 Medium 2×106 High 6×106&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 24, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency and severity of toxicities and adverse events</measure>
    <time_frame>24 weeks</time_frame>
    <description>To assess the frequency and severity of toxicities and adverse events according to NCI CTC v4.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall response rate</measure>
    <time_frame>24 week</time_frame>
    <description>To assess the overall response rate after CD19 CAR T infusion in R/R B cell malignancies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>24 week</time_frame>
    <description>To assess the overall survival in patients with R/R B cell malignancies</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">9</enrollment>
  <condition>B-cell Malignancy</condition>
  <condition>B-cell Lymphoma</condition>
  <condition>B-Cell Acute Lymphoblastic Leukaemia</condition>
  <arm_group>
    <arm_group_label>CD19 CAR T</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CD19 CAR T cells transduced with a lentiviral vector to express anti-CD19 scFv CD3z:CD28 administered by IV infusion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CD19 CAR T</intervention_name>
    <description>CD19 CAR T cells transduced with a lentiviral vector to express anti-CD19 scFv CD3z:CD28 administered by IV infusion. Subjects will receive 0.1-10 x 10^6 transduced CAR T cells as a split dose over three days as follows:Day 1, 10% fraction, Day 2, 30% fraction, Day 3, 60% fraction.</description>
    <arm_group_label>CD19 CAR T</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. CD19+ relapsed or refractory B cell malignancies:&#xD;
&#xD;
               -  Relapsed or refractory B acute lymphocytic leukemia.&#xD;
&#xD;
                    -  Relapse was defined as presence of &gt; 5% blasts at screening, or second or&#xD;
                       subsequent bone marrow relapse, or any bone marrow relapse after allogeneic&#xD;
                       stem cell transplant and must be ≥ 6 months from stem cell transplant at the&#xD;
                       time of infusion.&#xD;
&#xD;
                    -  Refractory was defined by not achieving an initial complete response after 2&#xD;
                       cycles of a standard chemotherapy regimen . Patients who were refractory to&#xD;
                       subsequent chemotherapy regimens after an initial remission were considered&#xD;
                       chemorefractory&#xD;
&#xD;
               -  Patients with Ph+ acute lymphocytic leukemia were eligible if they are intolerant&#xD;
                  to or have not achieved a remission after two lines of tyrosine kinase inhibitor&#xD;
                  therapy, or if tyrosine kinase inhibitor therapy is contraindicated, or&#xD;
                  ineligible for allogeneic stem cell transplant because of:&#xD;
&#xD;
                    -  Comorbid disease&#xD;
&#xD;
                    -  Other contraindications to allogeneic stem cell transplant conditioning&#xD;
                       regimen&#xD;
&#xD;
                    -  Lack of suitable donor&#xD;
&#xD;
                    -  Prior hematopoietic stem cell transplant&#xD;
&#xD;
                    -  Declined allogeneichematopoietic stem cell transplant as a therapeutic&#xD;
                       option&#xD;
&#xD;
               -  Relapsed or refractory non-Hodgkin's lymphoma&#xD;
&#xD;
                    -  Histopathological CD19+.&#xD;
&#xD;
                    -  No response to last line of therapy i. partial response as best response to&#xD;
                       most recent therapy regimen ii. partial response as best response to most&#xD;
                       recent therapy with duration no longer than 6 month from last dose of&#xD;
                       therapy&#xD;
&#xD;
                    -  Refractory post-Autologous stem cell transplant i. Disease progression or&#xD;
                       relapsed less than or equal to 12 months of Autologous stem cell transplant&#xD;
                       (must have biopsy proven recurrence in relapsed subjects) ii. If salvage&#xD;
                       therapy is given post-Autologous stem cell transplant, the subject must have&#xD;
                       had no response to or relapsed after the last line of therapy&#xD;
&#xD;
                    -  Subjects must have received adequate prior therapy including at a minimum:&#xD;
                       anti-CD20 monoclonal antibody unless investigator determines that tumor is&#xD;
                       CD20-negative and an anthracycline containing chemotherapy regimen for&#xD;
                       subjects with transformed follicular lymphoma must have received prior&#xD;
                       chemotherapy for follicular lymphoma and subsequently have chemorefractory&#xD;
                       disease after transformation to Diffuse large B-cell lymphoma&#xD;
&#xD;
               -  At least one measurable lesion per revised IWG Response Criteria&#xD;
&#xD;
          2. 18-75 years old&#xD;
&#xD;
          3. Expected survival ≥ 12 weeks&#xD;
&#xD;
          4. Adequate renal, hepatic, pulmonary and cardiac function defined as:&#xD;
&#xD;
               -  Creatinine clearance (as estimated by Cockcroft Gault) &gt; 60 mL/min&#xD;
&#xD;
               -  Serum ALT/AST &lt;2.5 ULN&#xD;
&#xD;
               -  Total bilirubin &lt;1.5 mg/dl, except in subjects with Gilbert's syndrome&#xD;
&#xD;
               -  Cardiac ejection fraction &gt;50%, no evidence of pericardial effusion as determined&#xD;
                  by an echocardiogram, and no clinically significant pleural effusion&#xD;
&#xD;
               -  Baseline oxygen saturation &gt;92% on room air&#xD;
&#xD;
          5. Eastern cooperative oncology group (ECOG) performance status of 0 - 2&#xD;
&#xD;
          6. Pregnant or lactating women must have a negative pregnancy test before infusion, and&#xD;
             agree to take effective contraception during the trial&#xD;
&#xD;
          7. Apheresis product received and accepted&#xD;
&#xD;
          8. Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Isolated extra-medullary relapse leukemia&#xD;
&#xD;
          2. Other malignancies&#xD;
&#xD;
          3. Concomitant genetic syndrome, with the exception of Down Syndrome&#xD;
&#xD;
          4. Burkitt's lymphoma/leukemia&#xD;
&#xD;
          5. Treatment with any prior gene therapy product, anti-CD19/anti-CD3 therapy, or any&#xD;
             other anti-CD19 therapy&#xD;
&#xD;
          6. Active hepatitis B, C, or any uncontrolled infection&#xD;
&#xD;
          7. Grade 2 to 4 Graft versus Host Disease (GVHD)&#xD;
&#xD;
          8. Medications or treatments that were to be excluded:&#xD;
&#xD;
               -  Corticosteroids within 72 hours of infusion, with the exception of physiologic&#xD;
                  replacement&#xD;
&#xD;
               -  Allogeneic cellular therapy, such as donor lymphocyte infusion within 6 weeks&#xD;
                  prior to infusion&#xD;
&#xD;
               -  Graft versus Host Disease therapies&#xD;
&#xD;
               -  Chemotherapy stopped prior to lymphodepletion based on clearance&#xD;
&#xD;
               -  central nervous system prophylaxis treatment&#xD;
&#xD;
          9. Active central nervous system disease (central nervous system 2 disease [Cerebral&#xD;
             spinal fluid containing blasts, but &lt; 5 WBCs/microliter] patients were eligible)&#xD;
&#xD;
         10. Any condition that investigator considered may increase the risk of the subjects or&#xD;
             interfere with the trial results&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ligen Liu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Tong Ren Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ligen Liu</last_name>
    <phone>18017337037</phone>
    <email>llg3532@shtrhospital.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai Tong Ren hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ligen Liu</last_name>
      <phone>18017337037</phone>
      <email>llg3532@shtrhospital.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>May 30, 2018</study_first_submitted>
  <study_first_submitted_qc>June 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2018</study_first_posted>
  <last_update_submitted>November 3, 2020</last_update_submitted>
  <last_update_submitted_qc>November 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Tong Ren Hospital</investigator_affiliation>
    <investigator_full_name>Liu Ligen</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

